» 2019-03-05

Pharmaceutical major Lupin and partner Natco Pharma received approval from the US Food and Drug Administration (FDA) to sell a generic equivalent of Novartis Pharmaceuticals’ Gleevec cancer tablets in the […]

» 2019-01-21

Indian pharmaceuticals manufacturer Wockhardt said it received approval from the United States Food & Drug Administration to launch a generic version of Novartis’ Leukemia drug Gleevec. The drug is estimated […]

» 2017-12-08

Glenmark Pharmaceuticals said it has started the clinical trial of its blood cancer drug GBR 1342 with the dosing of the first patient. “In just the last year, three of […]

» 2017-11-23

Pharmaceutical company Biocon has launched KRABEVA, a biosimilar Bevacizumab for the treatment of patients a variety of cancers in India. The biosimilar — or a drug that mimics a natural […]

» 2017-06-21

Glenmark Pharmaceuticals said it entered into a licensing agreement with Boston-based biopharmaceutical company APC Therapeutics Inc for exclusive rights for a cancer drug. The agreement covers a small molecule based […]

» 2017-03-10

The number of cancer cases in India jumped by 4.5% in 2016 to 14.51 lakh, according to the Indian Council of Medical Research or ICMR. The number implies that 1 […]

» 2016-11-09

Mylan N.V. and Biocon Ltd. said they submitted Mylan’s biologics license application for a proposed biosimilar Trastuzumab, to the U.S. Food and Drug Administration. Biosimilar trastuzumab is a proposed biosimilar […]

» 2014-08-20

Glenmark Pharmaceuticals has announced the discovery of a new anti-cancer therapy by its Swiss subsidiary. The new drug, GBR 1302, will target breast cancer and ovarian cancer, and the company […]